Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dunn

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
AIDS (London, England)|November 15, 2017
Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistanceSara Lodi, Huldrych F Günthard, David Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazolesPaul Ratcliffe, Lynn Abernethy, Nasrin Ansari, et al.
HIV Medicine|August 30, 2016
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015Duncan Churchill, Laura Waters, Nadia Ahmed, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2016
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimenAndrea De Luca, Philippe Flandre, David Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2011
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonistsRonald Palin, Lynn Abernethy, Nasrin Ansari, et al.
The Lancet. Infectious Diseases|March 1, 2011
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyLinda Wittkop, Huldrych F Günthard, Frank de Wolf, et al.
Plos Medicine|September 21, 2011
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyVijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, et al.
AIDS (London, England)|May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVLeanne McCabe, James E Burns, Arash Latifoltojar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2026
A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trialSheena McCormack, David Dunn, Sylvia Kusemererwa, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
AIDS (London, England)|November 15, 2017
Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistanceSara Lodi, Huldrych F Günthard, David Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazolesPaul Ratcliffe, Lynn Abernethy, Nasrin Ansari, et al.
HIV Medicine|August 30, 2016
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015Duncan Churchill, Laura Waters, Nadia Ahmed, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2016
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimenAndrea De Luca, Philippe Flandre, David Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2011
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonistsRonald Palin, Lynn Abernethy, Nasrin Ansari, et al.
The Lancet. Infectious Diseases|March 1, 2011
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyLinda Wittkop, Huldrych F Günthard, Frank de Wolf, et al.
Plos Medicine|September 21, 2011
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyVijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, et al.
AIDS (London, England)|May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVLeanne McCabe, James E Burns, Arash Latifoltojar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2026
A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trialSheena McCormack, David Dunn, Sylvia Kusemererwa, et al.
Pageof 15